Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib

Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed patients with chronic myeloid leukemia. In recent years, several second-generation inhibitors – such as dasatinib and nilotinib – have become available: these promise to overcome some of the mutations a...

Full description

Bibliographic Details
Published in:	Haematologica
Main Authors:	Adam Olshen, Min Tang, Jorge Cortes, Mithat Gonen, Timothy Hughes, Susan Branford, Alfonso Quintás-Cardama, Franziska Michor
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2014-11-01
Online Access:	https://haematologica.org/article/view/7198

Similar Items

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: B. Uz, et al.
Published: (2011-01-01)

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
by: G Rogers, et al.
Published: (2012-04-01)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
by: Fang Cheng, et al.
Published: (2023-04-01)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Radhakrishnan Ramchandren, et al.
Published: (2009-05-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
by: Min Tang, et al.
Published: (2012-10-01)

A validated UPLCâMS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
by: Jing Zeng, et al.
Published: (2017-12-01)

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
by: Meenakshi Sachdeva, et al.
Published: (2023-10-01)

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
by: Francesca Palandri, et al.
Published: (2009-12-01)

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network
by: Rafael Amorim Belo Nunes, et al.
Published: (2023-02-01)

Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
by: Tayfur Toptas, et al.
Published: (2025-12-01)

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
by: Thomas Ernst, et al.
Published: (2009-09-01)

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
by: Antonella Russo Rossi, et al.
Published: (2013-03-01)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
by: Ali Ibrahim, et al.
Published: (2022-05-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA
by: F. Pane, et al.
Published: (2022-06-01)

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
by: Chung H. Kok, et al.
Published: (2023-09-01)

Nilotinib therapy after resistance to imatinib
by: Raffaele Porrini, et al.
Published: (2015-10-01)

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
by: Timothy P. Hughes, et al.
Published: (2014-07-01)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021-11-01)

Extending the reach of nilotinib in chronic myeloid leukemia
by: Michael J. Mauro
Published: (2014-07-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib
by: Paul La Rosée, et al.
Published: (2008-05-01)

Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN
by: Jorge E. Cortes, et al.
Published: (2024-05-01)

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach
by: Mario Annunziata
Published: (2015-10-01)

Use of dasatinib in chronic myeloid leukemia therapy
by: O. Yu. Vinogradova, et al.
Published: (2008-12-01)

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
by: Thoralf Lange, et al.
Published: (2013-05-01)

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
by: Beatriz Felicio Ribeiro, et al.
Published: (2015-08-01)

P202 | FRONTLINE NILOTINIB VS DASATINIB IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: A PROPENSITY SCORE ANALYSIS BASED ON AIFA MONITORING REGISTRIES
by: M. Breccia, et al.
Published: (2025-09-01)

Expanding dasatinib beyond KIT in acute myeloid leukemia
by: John S. Welch
Published: (2020-12-01)

Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en leucemia mieloide crónica en Colombia, 2012
by: Martín Romero, et al.
Published: (2014-03-01)

Serum Levels of Advanced Oxidation Protein Products and some Liver Function Markers in Chronic Myeloid Leukemia-Chronic Phase Patients Receiving Imatinib or Nilotinib
by: Ikhlas Khammas, et al.
Published: (2025-06-01)

Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
by: Alice Fabarius, et al.
Published: (2007-06-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells
by: Devendra K. Hiwase, et al.
Published: (2013-06-01)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
by: Güldane Seval, et al.
Published: (2017-05-01)

Nilotinib Induced Keratosis Pilaris in a Female With Chronic Myeloid Leukemia
by: Ranjana Beniwal, et al.
Published: (2024-04-01)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
by: Ilaria S. Pagani, et al.
Published: (2018-12-01)